{"schema_version":"secwatch.filing_event.v1","accession":"0001178670-25-000020","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.095903+00:00","generated_at":"2026-05-26T22:06:12.353851+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Alnylam Q4 product rev $451M (+30%); FY rev $1.65B (+33%); vutrisiran sNDA PDUFA Mar 23","bullets":["Q4 2024 global net product revenues $451M (+30% vs Q4 2023); full year $1,646M (+33%).","Q4 total revenues $593.2M; net loss $83.8M improved from $137.9M loss in Q4 2023.","FDA accepted sNDA for vutrisiran in ATTR cardiomyopathy; PDUFA target date March 23, 2025.","Non-GAAP net income of $8.0M in Q4 vs loss of $96.6M in prior year.","Company reiterates 2025 product sales and profitability guidance; R&D Day Feb 25, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001178670-25-000020","json":"https://secwatch.observer/filing/0001178670-25-000020.json","markdown":"https://secwatch.observer/filing/0001178670-25-000020.md","text":"https://secwatch.observer/filing/0001178670-25-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000117867025000020/0001178670-25-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000117867025000020/alny-20250213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:06:12.353851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}